Anti-inflammatory activity of serum cytokines (IL-4, IL-10, IL-13) and the natural IL-1p receptor antagonist (IL-1Ra) in women with uterine myoma


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To investigate serum levels of anti-inflammatory cytokines (interleukins (IL) -4, IL-10, IL-13) and a natural IL-1ß receptor antagonist (IL-1Ra) in women with uterine myoma using multiplex analysis. Material and methods. The study comprised 36 women with uterine myoma aged 23 to 54 years. All women underwent general clinical and standard diagnostic examination, hemostatic testing, and cytokine profiling (Bio-Plex 200). Results. The women with uterine myoma had significantly decreased serum levels of IL-4 (p <0.000001) and IL-1Ra (p = 0.00002). Serum levels of the two other cytokines, IL-10 and IL-13, were within normal range. Conclusion. Low concentrations of factors inhibiting tissue inflammation and angiogenesis can produce an unfavorable effect on the proliferation and differentiation of uterine tissues. Low levels of the anti-inflammatory component of a cytokine network can also be one of the factors contributing to the development of chronic infectious and inflammatory processes in women with uterine myoma.

Full Text

Restricted Access

About the authors

Vladimir I. Konenkov

Research Institute of Clinical and Experimental Lymphology, Affiliated Branch of FRC of Cytology and Genetics, Siberian Division of the RAS

Email: vikonenkov@gmail.com
Dr.Med.Sci. Professor, Academician of the RAS, the Honored Scientist of the RF, Academic Administrator

Elena G. Koroleva

Research Institute of Clinical and Experimental Lymphology, Affiliated Branch of FRC of Cytology and Genetics, Siberian Division of the RAS

Email: lymphology@niikel.ru
Researcher at the Laboratory of Cell Technologies

Nikolai B. Orlov

Research Institute of Clinical and Experimental Lymphology, Affiliated Branch of FRC of Cytology and Genetics, Siberian Division of the RAS

Email: nbo700@mail.ru
Ph.D., Senior Researcher at the Laboratory of Clinical Immunogenetics

Viktor F. Prokof’ev

Research Institute of Clinical and Experimental Lymphology, Affiliated Branch of FRC of Cytology and Genetics, Siberian Division of the RAS

Email: vf_prok@mail.ru
Ph.D., Leading Researcher at the Laboratory of Clinical Immunogenetics

Alla V. Shevchenko

Research Institute of Clinical and Experimental Lymphology, Affiliated Branch of FRC of Cytology and Genetics, Siberian Division of the RAS

Email: shalla64@mail.ru
Dr.Bio.Sci., Leading Researcher at the Laboratory of Clinical Immunogenetics

Aleksei M. Novikov

Research Institute of Clinical and Experimental Lymphology, Affiliated Branch of FRC of Cytology and Genetics, Siberian Division of the RAS

Email: novis.ngmu@gmail.com
Ph.D., Junior Researcher at the Laboratory of Clinical Immunogenetics

Tat’yana I. Dergacheva

Research Institute of Clinical and Experimental Lymphology, Affiliated Branch of FRC of Cytology and Genetics, Siberian Division of the RAS

Email: dr-tanja@yandex.ru
Dr.Med.Sci., Professor, Leading Researcher at the Laboratory of Functional Morphology of the Lymphatic System

Aleksandr A. Ostanin

Research Institute of Clinical and Experimental Lymphology, Affiliated Branch of FRC of Cytology and Genetics, Siberian Division of the RAS

Email: ct_lab@mail
Dr.Med.Sci., Professor, Chief Researcher at the Laboratory of Cellular Immunotherapy

References

  1. Manyonda I., Sinthamoney E., Belli A.M. Controversies and challenges in the modern management of uterine fibroids. BJOG. 2004; 111(2): 95-102.
  2. Stewart E.A. Uterine fibroids. Lancet. 2001; 357(9252): 293-8.
  3. Zowall H., Cairns J.A., Brewer C., Lamping D.L., Gedroyc W.M., Regan L. Cost-effectiveness of magnetic resonance-guided focused ultrasound surgery for treatment of uterine fibroids. BJOG. 2008; 115(5): 653-62.
  4. Van der Kooij S.M., Ankum W.M., Hehenkamp W.J. Review of nonsurgical/minimally invasive treatments for uterine fibroids. Curr. Opin. Obstet. Gynecol. 2012; 24(6): 368-75.
  5. Rabinovici J., David M., Fukunishi H., Morita Y., Gostout B.S., Stewart E.A. Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. Fertil. Steril. 2010; 93(1): 199-209.
  6. Gavrilova-Jordan L.P., Rose C.H., Traynor K.D., Brost B.C., Gostout B.S. Successful term pregnancy following MR-guided focused ultrasound treatment of uterine leiomyoma. J. Perinatol. 2007; 27(1): 59-61.
  7. Кузнецова М.В., Трофимов Д.Ю., Тихончук Е.Ю., Согоян Н.С., Адамян Л.В., Сухих Г.Т. Молекулярные механизмы патогенеза миомы матки: анализ мутаций гена MED 12 в российской популяции. Акушерство и гинекология. 2016; 10: 85-90. http://dx.doi. org/10.18565/aig.2016.10.85-90
  8. Protic O., Toti P., Islam M.S., Occhini R., Giannubilo S.R., Catherine W.H. et al. Possible involvement of inflammatory/reparative processes in the development of uterine fibroids. Cell Tissue Res. 2016; 364(2): 415-27.
  9. Biancotto A., Wank A., Perl S., Cook W., Olnes M.J., Dagur P.K. et al. Correction: Baseline levels and temporal stability of 27 multiplexed serum cytokine concentrations in healthy subjects. PLoS One. 2015; 10(7): e0132870.
  10. Annunziato F., Romagnani C., Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J. Allergy Clin. Immunol. 2015; 135(3): 626-35.
  11. Björkström N.K., Kekäläinen E., Mjösberg J. Tissue-specific effector functions of innate lymphoid cells. Immunology. 2013; 139(4): 416-27.
  12. Bamias G., Cominelli F. Role of Th2 immunity in intestinal inflammation. Curr. Opin. Gastroenterol. 2015; 31(6): 471-6.
  13. Hall B.M. T. cells: soldiers and spies - the surveillance and control of effector T. cells by regulatory T. cells. Clin. J. Am. Soc. Nephrol. 2015; 10(11): 2050-64.
  14. Palomo J., Dietrich D., Martin P., Palmer G., Gabay C. The interleukin (IL)-1 cytokine family-Balance between agonists and antagonists in inflammatory diseases. Cytokine. 2015; 76(1): 25-37.
  15. Iyer S.S., Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit. Rev. Immunol. 2012; 32(1): 23-63.
  16. Sabat R., Grütz G., Warszawska K., Kirsch S., Witte E., Wolk K. et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010; 21(5): 331-44.
  17. O’Garra A., Barrat F.J., Castro A.G., Vicari A., Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunol. Rev. 2008; 223: 114-31.
  18. Wang X., Qin J., Chen J., Wang L., Chen W., Tang L. The effect of high-intensity focused ultrasound treatment on immune function in patients with uterine fibroids. Int. J. Hyperthermia. 2013; 29(3): 225-33.
  19. Pradillo J.M., Murray K.N., Coutts G.A., Moraga A., Oroz-Gonjar F., Boutin H. et al. Reparative effects of interleukin-1 receptor antagonist in young and aged/comorbid rodents after cerebral ischemia. Brain Behav. Immun. 2017; 61: 117-26.
  20. Fiocco U., Vezzù M., Cozzi L., Todesco S. IL-1Ra (recombinant human IL-1 receptor antagonist) in the treatment of rheumatoid arthritis: the efficac. Reumatismo. 2004; 56(1, Suppl. 1): 62-73.
  21. Garg M., de Jesus A.A., Chapelle D., Dancey P., Herzog R., Rivas-Chacon R. et al. Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist. JCI Insight. 2017; 2(16). pii: 94838.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies